OncoMatch/Clinical Trials/NCT05950802
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Is NCT05950802 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Cyclophosphamide for dlbcl - diffuse large b cell lymphoma.
Treatment: Cyclophosphamide — This is a Phase 1b study of participants with Diffuse Large B Cell Lymphoma (DLBCL). The purpose of this study is to identify an optimized lymphodenpletion (LD) regimen by evaluating standard and intermediate doses of Fludarabine (Flu) / Cyclophosphamide (Cy) with or without a fixed dose of total lymphoid irradiation (TLI) in the setting of standard of care CAR T cell therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-CD20 therapy — first-line
Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative
Must have received: anthracycline — first-line
An anthracycline containing chemotherapy regimen
Cannot have received: adoptive T-cell immunotherapy
Patient has not received prior adoptive T-cell immunotherapy
Cannot have received: allogeneic stem cell transplant
Patient did not receive prior allogeneic stem cell transplant
Cannot have received: CD19 targeted therapy
Prior CD19 targeted therapy
Cannot have received: chimeric antigen receptor therapy or other genetically modified T-cell therapy
Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify